Salles Speaks to the Potential Benefit of the Tafasitamab Combo in the R/R DLBCL Setting – Targeted Oncology

On July 31, 2020, the FDA granted accelerated approval to the combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.1 The approval was granted based on findings from the phase 2 L-MIND trial that assessed the safety and efficacy of the combination of tafasitamab and lenalidomide in patients with relapsed/refractory DLBCL who had received 2 prior lines of therapy, including a CD20-directed therapy, and who are ineligible for high-dose chemotherapy and autologous stem cell transplantation. In this trial, the trial induced an objective response rate of 60%, with complete responses in 43%. The median duration of response was 21.7 months and 72% had a response lasting at least a year.2 The median progression-free survival (PFS) was 12.1 months with a 50% PFS rate at 1 year and 46% at 18 months.

Read more
Researcher is exploring safer and more effective treatment for leukemia – News-Medical.Net

A potentially safer, more effective chemotherapy treatment for patients with blood-related cancers, such as leukemia, who need a particular bone marrow transplant procedure is under study at the University of Arizona Health Sciences. The procedure is known as a haploidentical (half-matched) bone marrow transplantation, or "haplo-BMT," providng an alternative source of stem cells for patients who need a bone marrow transplant but are unable to find a perfect or near-perfect donor match for human leukocyte antigens (HLA)

Read more
‘Self-eating’ stem cell process may be the key to new regenerative therapies – Penn Today

The self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs,Penn Medicineresearchers show in a new study published online inScience. Human bodies contain more than 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency.

Read more
Potential COVID-19 cell therapy treatments in development – BioWorld Online

Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases. In an Alliance for Regenerative Medicine (ARM) webinar on the topic, Michael Lehmicke, director, science and industry affairs at ARM, noted that developers are utilizing mesenchymal stem cells (MSCs) and other stromal cells to treat ARDS caused by COVID-19. The number of clinical trials now underway continues to increase with many more at the preclinical stage

Read more
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – PRNewswire

NEW YORK, July 27, 2020 /PRNewswire/ --BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

Read more